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Paricalcitol for reduction 
of albuminuria in 
diabetes
Albeit based on robust methods, the 
study by Dick de Zeeuw and colleagues 
(Nov 6, p 2010)1 raises several 
concerns. First, little attention is given 
to the fact that the primary endpoint—
ie, the eﬀ ect of the vitamin D receptor 
activator (VDRA) on urinary albumin-
to-creatinine ratio (UACR)—is actually 
negative. The positive results on 
secondary endpoints should thus be 
used only to generate new hypotheses, 
not to support the eﬃ  cacy of the 
intervention. Besides, any reduction 
in UACR must also be interpreted in 
the context of its biological variation 
in patients with diabetes, which is 
estimated at 61%.2
Second, the mean concentration 
of vitamin D in the patients included 
(40 nmol/L) is far below the current 
recommendations3,4 and reﬂ ects a 
severe deﬁ ciency. Subgroup analysis 
according to the 25-hydroxyvitamin D 
concentration would be of interest.
Third, the cost-eﬀ ectiveness of 
a strategy based on paricalcitol in 
this indication has to be balanced 
with the use of the much cheaper 
native vitamin D for which there are 
physiological reasons to expect some 
eﬃ  cacy.5
Finally, the long-term safety of this 
strategy is questionable. Paricalcitol 
logically decreased concentrations 
of parathyroid hormone (from 
90·7 to 40 μg/L in the 2 μg group). 
These supraphysiological doses of 
selective VDRA could increase the 
risk of low bone turnover (with the 
inherent increased risk of vascular 
calciﬁ cations). Data on calciuria would 
be valuable in this regard. Risk of renal 
stones or nephrocalcinosis in the long 
term should also be discussed.
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In the VITAL study,1 Dick de Zeeuw and 
colleagues conclude that paricalcitol 
could be a novel approach to lower 
residual albuminuria and renal risk in 
patients with diabetes. However, several 
facts undermine this suggestion.
First, the reduction in urinary albumin-
to-creatinine ratio (UACR) from baseline 
to last measurement did not reach 
signiﬁ cance (p=0·053). Second, the 
proportion of patients who achieved at 
least a 15% UACR reduction in the same 
time would be non-signiﬁ cant if only 
one additional patient from the 2 μg 
paricalcitol group had not met this goal. 
Third, it seems that a relatively high 
paricalcitol dose (2 μg/day) is needed for 
any antiproteinuric eﬀ ect to be shown 
since the 1 μg group did not have such 
an eﬀ ect. Of note, the 2 μg group had a 
signiﬁ cantly higher dropout rate owing 
to adverse events than the 1 μg and 
placebo groups, and all three deaths in 
the study occurred in the 2 μg group. 
Finally, although signiﬁ cant, the small 
reduction (254 mg) in the mean 24-h 
urinary albumin between baseline 
and the last measurement in the 2 μg 
group cannot be regarded as clinically 
signiﬁ cant until the emergence of 
larger and longer-duration random ised 
controlled trials to assess hard endpoints 
such as renal or overall survival.
In my opinion the use of high-dose 
paricalcitol for the prevention of renal 
damage in patients with diabetes and 
chronic kidney disease is of uncertain 
eﬃ  ciency and safety and thus should 
not be recommended on the basis of 
the current data.
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We have two issues with the design 
and presentation of the VITAL trial.1 
First, most patients enrolled in VITAL 
were vitamin D insuﬃ  cient (mean 
25-hydroxyvitamin D concentration 
40–42 nmol/L). The therapeutic or 
adverse eﬀ ect pattern might not 
be extrapolated to patients who 
are vitamin D suﬃ  cient. Thus, we 
suggest the conclusions be changed 
to “paricalcitol…safely lowers residual 
albuminuria in vitamin D insuﬃ  cient 
patients with diabetic nephropathy”.
25-hydroxyvitamin D insuﬃ  ciency is 
associated with adverse outcomes, and 
vitamin D supple mentation decreases 
inﬂ ammation even in dialysis patients, 
probably through local, auto, or 
paracrine activity of extrarenal calcitriol 
generation.2 Calcitriol protects podo- 
cytes and has shown antialbuminuric 
eﬀ ects in preclinical studies.3,4 Thus, 
it is unclear to what extent the noted 
therapeutic eﬀ ects of paricalcitol are the 
result of correction of deﬁ cient activa-
tion of vitamin D receptors caused by 
vitamin D insuﬃ  ciency or of a therapeutic 
action beyond what might be achieved 
by restoring 25-hydroxyvitamin D. 
Guidelines available at the time of 
study design suggest that vitamin D 
supplementation should be started 
when serum 25-hydroxyvitamin D is 
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Dick de Zeeuw and colleagues1 report 
that oral admini stration of 2 μg/day 
paricalcitol for 24 weeks safely lowers 
residual albuminuria in patients 
treated with inhibitors of the renin-
angiotensin-aldosterone system for 
diabetic nephropathy.
Although de Zeeuw and colleagues 
provide a wide range of data, they 
do not report serum phosphorus 
concentrations during the 24 weeks 
of paricalcitol administration. Since 
observational studies have shown 
that higher concentrations correlate 
with mortality in diabetic populations 
with and without renal disease,2,3 
their value might be of extreme 
importance.
Another issue that also needs 
underlining is that diabetic patients 
with end-stage renal disease (ESRD) 
often have low-turnover bone disease. 
Long-term paricalcitol administration 
during the months or years before 
reaching ESRD might aggravate 
adynamic bone disease (a diﬃ  cult-to-
reverse form of renal bone disease) in 
diabetic patients who will eventually 
need dialysis.
Despite the encouraging results of 
de Zeuuw and colleagues’ study, long-
term clinical trials with oral paricalcitol 
in patients with diabetes and renal 
disease are urgently warranted, and 
with more meaningful endpoints such 
as mortality or ESRD.
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Authors’ reply
The VITAL study reported that 
paricalcitol lowers albuminuria in 
patients with type 2 diabetes and 
residual high albuminuria after 
guideline therapy, including an 
inhibitor of the renin-angiotensin-
aldosterone system. The reason why 
we interpreted the antialbuminuric 
data with somewhat more 
conﬁ dence than do Pierre Delanaye 
and colleagues and Theodoros 
Kassimatis has to do with the 
fact that paricalcitol’s eﬀ ect (in 
particular the 2 μg dose) is highly 
signiﬁ cant when looking at 24-h 
urine albuminuria, and looking at 
urinary albumin-to-creatinine ratio 
(UACR) eﬀ ects over all timepoints 
available. As mentioned by Delanaye 
and colleagues and Kassimatis, the 
eﬀ ect size and the power of the study 
are not high, and we fully agree that 
VITAL is a hypothesis-generating 
study with a strong argument 
to do a ﬁ nal study on hard renal 
endpoints.
We thank Alberto Ortiz and 
colleagues for calling attention to 
the fact that most patients with 
chronic kidney disease (CKD) are 
vitamin D deﬁ cient. This point makes 
it im possible to assess the eﬃ  cacy 
of paricalcitol in those who were 
vitamin D replete. As mentioned in 
our Article, a study with calcitriol did 
also show modest antiproteinuric 
eﬀ ects in IgA nephropathy.1 Future 
comparative studies should establish 
whether the eﬀ ect of raising 
25-hydroxyvitamin D concentrations 
with cholecalciferol or ergocalciferol 
can reduce albuminuria to a similar 
extent to paricalcitol.
Regarding paricalcitol dose 
reductions in our trial, the protocol 
speciﬁ ed that patients would have 
dose reductions in the event of over-
sup pres sion of parathyroid hormone 
or of hypercalcaemia. The ﬁ nding 
that dose reductions occurred in 
42% of patients in the 2 μg group 
indicates that the majority were able 
to receive high-dose paricalcitol 
throughout. The 2 μg group did show 
the antialbuminuric eﬀ ects despite 
this down-titration.
Although we agree with Costas 
Fourtounas that observational 
studies in CKD patients have shown 
associations between higher serum 
phosphate concentrations and 
increased mortality in patients who 
are mostly vitamin D deﬁ cient,2 
Second, the potential adverse eﬀ ects 
of paricalcitol on mineral metabolism are 
not carefully documented. Apparently 
there were no pre-estab lished criteria 
for dose reduction. Thus we wonder 
what triggered dose reduction in 
patients assigned to 2 μg/day, what 
were serum calcium and phosphate 
concentrations at the time of dose 
reduction, and whether additional 
biochemical abnormalities were 
present in patients with sup pressed 
parathyroid hormone con centrations.
Finally, the eﬀ ect of pari calcitol on 
serum phosphate concentrations or 
phosphate binder use is con spicuously 
missing.
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